Bridge Biotherapeutics filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to start a Phase 1 trial of its idiopathic pulmonary fibrosis (IPF) treatment candidate BBT-877 in January. BBT-877 is an inhibitor of the enzyme autotaxin (ATX). This enzyme is relevant…
News
Evidence that the IGFBP-5 protein contributes to the development of pulmonary fibrosis was supported by new research finding that its higher-than-normal levels in people with fibrotic disease help to drive other pro-fibrotic proteins and factors. The study, “IGFBP-5 Promotes Fibrosis via Increasing Its Own Expression and That…
A new small molecule inhibitor of the LOXL2 enzyme, developed by Pharmaxis, is safe and holds potential to treat fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non‐alcoholic steatohepatitis (NASH), according to results from a Phase 1 trial. The study (ACTRN12617001564347) enrolled 48 healthy volunteers who were…
Redx Pharma announced it soon give an update on early work on a potentially new type of idiopathic pulmonary fibrosis (IPF) treatment, called RXC006, that may help patients with advanced disease. Peter Bunyard, PhD, the company’s head of fibrosis, will present preclinical data at the 2nd Anti-Fibrotic…
Ofev (nintedanib) shows a similar ability to reduce lung function decline in patients with advanced idiopathic pulmonary fibrosis (IPF) as those with milder disease, according to a real-world clinical study. However, a higher number of patients with advanced IPF stopped Ofev treatment. The study, “Efficacy and…
A plant-derived compound called ouabain is a potential treatment for idiopathic pulmonary fibrosis (IPF), according to a recent study. Treatment with ouabain — more commonly used to treat certain heart conditions — alleviated IPF-related symptoms in mice. The study, “Ouabain ameliorates bleomycin induced pulmonary fibrosis by inhibiting…
A greater decline in lung function prior to treatment start may lead idiopathic pulmonary fibrosis (IPF) patients to stop using Ofev (nintedanib), as might older age, a real-world study from the United Kingdom found. “No predominant reason for discontinuation was identified in this group,” its researchers wrote, but it’s…
Genkyotex’s anti-fibrotic candidate GKT831 appears to be safe and hold therapeutic activity in an ongoing Phase 2 trial in patients with primary biliary cholangitis, an autoimmune-triggered fibrotic disease of the liver. These positive interim results support the development of GKT831 as a possible treatment of other fibrotic diseases,…
BML‐111, a potent activator of the natural anti-inflammatory lipoxin A4 receptor, protects lungs from fibrosis by inhibiting fibroblast activation and decreasing the levels of inflammatory signaling molecules, a mouse study shows. The study “BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo” was…
Results from the long-term PASSPORT clinical study are consistent with the known safety profile of Esbriet (pirfenidone), further strengthening the safety of the therapy in patients with idiopathic pulmonary fibrosis (IPF). After authorization by the European Medicine Agency (EMA), it was suggested that a large, long-term post-authorization study be conducted…
